Skip to main content

Unable to load price data. Sorry.


Emisphere Technologies, Inc. (NASDAQOTCBB:EMIS.DL)

CAPS Rating: No stars

A biopharmaceutical company specializing in the oral delivery of therapeutic macromolecules and other compounds that are poorly deliverable by oral means.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform

All-Star Players

0 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform


The best Bull and Bear pitches based on recency and number of recommendations.

rajny (< 20)
Submitted October 21, 2010

I can't argue with the thumbs-down pitches. This stock has held promise and has disappointed for years.However, if someone is looking for a high-risk, potentially high reward stock, EMIS is the biotech to look at...especially because it has been… More

TSIF (99.98)
Submitted February 11, 2019

May have some potential working with Novo Nordisk on applying their technology to oral insulin, but the low overhead from the (six) cited employees is being offset by the very high debt load. Data/Filings look stale, but last posted they had a neg… More



  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about EMIS.DL.

No one has written a Pitch for EMIS.DL stock yet. Tell us why you think EMIS.DL will outperform or underperform against the market.


Find the members with the highest scoring picks in EMIS.DL.

No players have picked EMIS.DL yet. Tell us why you think EMIS.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EMIS.DL.